ALUR

Allurion Technologies Inc

Add to Watchlist

Advanced Chart

1.260

0(0.000%)1D

Line

Candle

YTD

High

1.280

Open

1.280

VWAP

1.25

Vol

59.72K

Mkt Cap

11.67M

Low

1.250

Amount

74.91K

EV/EBITDA(TTM)

Total Shares

47.97M

37.77M

EV/OCF(TTM)

P/S(TTM)

0.41

Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

12.80M

+278.81%

-0.420

-51.9%

10.60M

+89.96%

-0.530

-56.9%

2.90M

-48.13%

-1.300

-81.41%

Estimates Revision

The market is revising Upward the revenue expectations for Allurion Technologies Inc. (ALUR) for FY2025, with the revenue forecasts being adjusted by 7.26% over the past three months. During the same period, the stock price has changed by -43.75%.

Revenue Estimates for FY2025

Revise Upward

+7.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-25.58%

In Past 3 Month

Stock Price

Go Down

-43.75%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.260

Low

6.00

Averages

6.00

High

6.00

Current: 1.260

Low

6.00

Averages

6.00

High

6.00

Chardan Capital

Keay Nakae

Hold

Maintains

$2.5

2025-03-27

Reason

Chardan Capital

Keay Nakae

Price Target

$2.5

2025-03-27

Maintains

Hold

Reason

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$16

2025-03-21

Reason

Roth MKM

Jason Wittes

Price Target

$16

2025-03-21

Reiterates

Strong Buy

Reason

Chardan Capital

Keay Nakae

Hold

Maintains

$2.5

2025-03-21

Reason

Chardan Capital

Keay Nakae

Price Target

$2.5

2025-03-21

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Allurion Technologies Inc (ALUR.N) is -0.29, compared to its 5-year average forward P/E of -1.52. For a more detailed relative valuation and DCF analysis to assess Allurion Technologies Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.52

Current PE

-0.29

Overvalued PE

0.76

Undervalued PE

-3.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.86

Undervalued EV/EBITDA

-5.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.09

Current PS

0.00

Overvalued PS

5.42

Undervalued PS

-1.24

Financials

Annual

Quarterly

FY2025Q3

YoY :

-50.48%

2.66M

Total Revenue

FY2025Q3

YoY :

-21.97%

-9.63M

Operating Profit

FY2025Q3

YoY :

-231.79%

11.87M

Net Income after Tax

FY2025Q3

YoY :

-56.41%

-1.53

EPS - Diluted

FY2025Q2

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q3

YoY :

-15.37%

49.06

Gross Profit Margin - %

FY2025Q3

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q3

YoY :

-366.50%

447.10

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

51.3K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

30.0K

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.5M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

51.3K

USD

Months

0-12

0.0

USD

Months

ALUR News & Events

Events Timeline

2025-11-18 (ET)

2025-11-18

09:37:32

Allurion teams up with ProSurg to introduce innovative weight loss method in Brazil

2025-11-12 (ET)

2025-11-12

08:10:36

Allurion Technologies announces Q3 earnings per share of $1.53, below consensus estimate of $2.45.

2025-11-11 (ET)

2025-11-11

08:53:48

Allurion Technologies shares progress on Smart Capsule approval status

News

4.5

11-18NASDAQ.COM

Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion

9.5

08-19NASDAQ.COM

Allurion Technologies, Inc. (ALUR) Announces Q2 Loss and Falls Short of Revenue Projections

9.0

06-17Newsfilter

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS